Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of DVRd followed by cilta-cel versus DVRd followed by autologous stem cell transplant in newly diagnosed transplant-eligible multiple myeloma
MOH_2023-07-03_011999Phase 3Not yet recruiting
- Sponsor
- European Myeloma Network
- Start
- Sep 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ciltacabtagene autoleucel in multiple myeloma (MM) (2 arms), sponsored by European Myeloma Network. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on MOH_2023-07-03_011999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-03_011999.